En
It
De
日本語
中文
Es
Abstract
The pharmaceutical and healthcare sector is evolving due to key trends: rising chronic disease rates, a shift toward home-based care, growth in biologics, and a transition from intravenous (IV) to subcutaneous (SC) drug delivery. These developments present major formulation and delivery challenges. Biologics like mAbs require higher volumes and concentrations to ensure stability and reduce dosing frequency, often leading to high viscosity.
Traditional containers are often unsuitable for addressing these hurdles. They fail to mitigate drug compatibility risks, which can potentially impact product stability over time and patient safety.
When selecting an appropriate container for biologic drug delivery, several critical factors must be considered to ensure both compatibility and performance. These include the target injection volume, the presence and concentration of excipients, and the seamless integration with existing delivery devices.
In this webinar, we’ll explore key challenges and present innovative solutions to enhance drug stability, patient comfort, and device performance.
We'll examine the features of syringe-based systems, including volume constraints and formulation risks, and introduce Stevanato Group’s Alba® platform. Thanks to its innovative crosslinked coating, this platform is designed to ensure consistent gliding force and minimize drug-container interactions.
We’ll also highlight how needle parameters must be selected to guarantee the required efficacy and safety while supporting patient comfort and therapy adherence, and how an optimized needle design, featuring a shorter length and an enlarged internal diameter, can result in lower injection forces and easier administration.
Finally, we will address scenarios where formulations exceed the volume limits of syringes or are sensitive to evaporation and precipitation. In such cases, cartridge-based systems offer an ideal alternative. With our extensive portfolio of Nexa® EZ-fill® (RTU) cartridge systems, featuring volumes from 1.5 to 20 mL, we offer versatile injection options tailored to diverse self-administration requirements in homecare environments, including pairing cartridges with on-body delivery systems.
Challenges this content will address
Learning Objectives
Enrico Barichello
Product Manager, Syringe Platform – DCS Business Unit, Stevanato Group
With a background in Industrial Engineering and a Master’s in Management at the University of Padua, Enrico Barichello acquired broad-spectrum skills in technical concepts and complex processes. He joined Stevanato Group in 2017 as a Product Management Specialist for the Syringe platform. He defined and coordinated all the activities required to bring the products to market, bridging gaps between different company functions and aligning the involved teams. He has been responsible for the roadmap and execution of the innovative platform Alba®. Since 2023 he is Product Manager for the Glass Syringe Platform.
Valerio Ravazzolo
Product Manager, Cartridge Platform – DCS Business Unit, Stevanato Group
With a background in Mechanical Engineering from the University of Padua, Valerio Ravazzolo joined Stevanato Group in 2015 as part of the Quality Assurance team. In 2017, he transitioned to a Technical Account Manager role, where he worked closely with key customers and progressively took on greater responsibilities, eventually becoming Team Manager. Building on this experience, he took the position of Product Manager for the cartridge platform, bringing together his technical expertise and customer-oriented mindset to drive product strategy and development.